Batten disease was the topic of the 12th Neurobiology of Disease in Children Symposium, held October 31, 2012, in Huntington Beach, California. Program codirectors Dr David Pearce and Dr Jonathan Mink prepared an engaging agenda that included individual presentations and a panel discussion from leaders in the field of neuronal ceroid lipofuscinoses.
These experts reviewed the clinical features of these conditions, discussed recent advances in understanding their pathogenesis, and described new investigations of characteristic symptoms. This was followed by a session on controversial topics and unanswered questions. The symposium concluded with a panel discussion led by scientific leaders in the field.
Dr Jonathan Mink opened the symposium with an overview of the neuronal ceroid lipofuscinoses, defining them as a broad class of diseases with many commonalities and moving deeper into specific classification schemes used to differentiate them. After the introduction, Dr Katherine Sims described the genetic mutations commonly associated with each neuronal ceroid lipofuscin disease. Dr Heather Adams then discussed the Unified Batten Disease Rating Scale, which is currently used to assess the physical, behavioral, and functional capabilities of children possessing JNCL mutations. Dr Adams went on to detail a study conducted with her group that analyzed the behavioral and social impact of a sample of 30 children with Batten disease. To conclude the first session, Dr Jonathan Cooper focused on the neuropathology of infantile and juvenile Batten disease, describing how changes in biological pathways related to astrocyte and microglial activation and glutamate-driven excitotoxicity can contribute to the neuronal loss seen in different mouse models of Batten disease.
The symposium's next session focused on progress in understanding the molecular mechanisms underlying various neuronal ceroid lipofuscin diseases. Dr Tammy Kielian detailed her work in isolating the inflammatory paradigm in juvenile Batten disease, highlighting monitoring of the effects of secretions of proinflammatory cytokines IL-1b in a mouse model that recapitulates the common 1-kb deletion found in the vast majority of these patients. Dr Kielian also elaborated on the contributions that aberrant astrocytes and faulty gap junctions make to neurotoxicity. Dr Pearce shared interesting findings about the localization and associations of the CLN3 protein.
The truncation of the CLN3 protein is a common result of the prominent 1-kb genetic deletion of the CLN3 gene. Although the true biological function of the CLN3 protein remains uncertain, scholars are beginning to identify the vast number of protein-protein interactions that CLN3 makes and note that these associations are highly variable depending on osmotic environmental stressors. Dr David Palmer concluded the session with his presentation on whether neuronal ceroid lipofuscin accumulations are a biomarker for or causative agent of disease progression. Dr Palmer also detailed the biochemical makeup of the ceroid lipofuscin storage material.
The symposium's third session focused on translational and clinical advances in neuronal ceroid lipofuscin research. Dr Beverly Davidson gave an overview of current gene therapy and enzyme replacement to address tripeptidyl peptidase deficiencies characteristic of late-infantile neuronal ceroid lipofuscin disease. This discussion addressed current advances in treatment options within animal models. Dr Mark Sands introduced contemporary studies on combinatorial therapies for treating infantile neuronal ceroid lipofuscin diseases. Many single-agent treatment regimens have been attempted and have been found to produce only limited effects. Infantile ceroid lipofuscin diseases are characterized by a deficiency in palmitoyl protein thioesterase-1 (PPT1). Combinations of AAVmediated gene therapy with a range of drugs were conducted with PPT1-deficient mice. Corresponding effects on life span and motor function were assessed.
To end the third session, Dr Erika Augustine discussed the challenges and opportunities inherent to rare disease clinical trials. Many roadblocks are associated with identifying good preclinical factors to discover target agents and establish potential therapies. Executing trials, securing funding, properly designing studies, and adopting appropriate measures and outcomes are also rife with common pitfalls. Dr Augustine highlighted certain private and governmental resources available to help circumvent these problems. Additionally, Dr Augustine closed with showcasing a series of rare disease clinical trials whose design feature addressed many of the rare disease features discussed. After an executive summary of the day's presentations by Drs Pearce and Mink, the conference concluded with a panel discussion moderated by Dr Mink that addressed future directions as well as remaining questions for the day's presenters.
The article written by Dolisca and colleagues in this issue offers a detailed review of each presentation as well as the verbatim transcript of the questions and answers after each session. The remainder of the article provides valuable insights into diagnosis and management of NCLs and future directions. Furthermore, each presenter recorded a video podcast summarizing his or her presentation, and the podcast was uploaded to the symposium website. 1 These video podcasts are outstanding updates in the field of Batten disease and provide a vision of the future work needed to move the field forward.
I express my sincere appreciation to the Batten Disease Support & Research Association, the National Institutes of Health (NIH), and the Child Neurology Society for cosponsoring the conference and the Young Investigator Program, which hosted 15 talented trainees and junior faculty with career interests in pediatric neurosciences and neuronal ceroid lipofuscinoses. I would also like to thank Dr Jonathan Mink of the University of Rochester for inspiring the young investigators and Dr Story Landis for her continued unwavering support of the Neurobiology of Disease in Children Symposium series.
Additionally, I am grateful for the wisdom and guidance of the symposium codirectors, Dr Mink and Dr Pearce. Lastly, I am humbled and thankful each year by the remarkable support of the Neurobiology of Disease in Children conferences and by the members of the Child Neurology Society.
I am pleased that Mitochondrial Diseases has been selected as the topic for the 13th Neurobiology of Disease in Children Symposium, which will be held on October 30, 2013, in Austin, Texas. Program codirectors Dr Bruce Cohen and Dr Bill Copeland have worked diligently to prepare an agenda that promises to meet or exceed expectations of loyal child neurology attendees as well as a new group of young investigators orienting to our field. We look forward to seeing you in the wonderful city of Austin.
